# Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
Canonical URL: https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025
Ticker: GPCR
Company: Structure Therapeutics
Source: Structure Therapeutics
Published: 2025-12-07 23:20 EST
Original Source URL: https://ir.structuretx.com
## Summary

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its

## Article Body
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its
## Recent Company News
- 2026-05-26 20:05 EST — [Structure Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/GPCR/structure-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Structure Therapeutics
- 2026-05-07 20:06 EST — [Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights) — Source: Structure Therapeutics
- 2026-04-27 20:05 EST — [Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions](https://biopharmsignal.com/news/GPCR/structure-therapeutics-to-present-aleniglipron-amylin-and-combination-data-at-the-american-diabetes-association-86th-scientific-sessions) — Source: Structure Therapeutics
- 2026-04-14 20:05 EST — [Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel](https://biopharmsignal.com/news/GPCR/structure-therapeutics-appoints-matthew-lang-j-d-as-chief-operating-officer-and-general-counsel) — Source: Structure Therapeutics
- 2026-03-16 11:00 EST — [Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron](https://biopharmsignal.com/news/GPCR/structure-therapeutics-reports-positive-topline-data-from-phase-2-access-ii-trial-with-once-daily-oral-small-molecule-glp-1-receptor-agonist-aleniglipron) — Source: Structure Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)